Adjuvant vemurafenib in resected, BRAF<sup>V600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

导出原文传递

翻译打印收藏纠错

第一作者： Michele,Maio

第一单位： Division of Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. Electronic address: mmaiocro@gmail.com.

作者： Michele,Maio ^[1] ; Karl,Lewis ^[2] ; Lev,Demidov ^[3] ; Mario,Mandalà ^[4] ; Igor,Bondarenko ^[5] ; Paolo A,Ascierto ^[6] ; Christopher,Herbert ^[7] ; Andrzej,Mackiewicz ^[8] ; Piotr,Rutkowski ^[9] ; Alexander,Guminski ^[10] ; Grant R,Goodman ^[11] ; Brian,Simmons ^[11] ; Chenglin,Ye ^[11] ; Yibing,Yan ^[11] ; Dirk,Schadendorf ^[12] ; BRIM8 Investigators

作者单位： Division of Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. Electronic address: mmaiocro@gmail.com. ^[1] University of Colorado Comprehensive Cancer Center, Aurora, CO, USA. ^[2] N N Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia. ^[3] Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. ^[4] Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine. ^[5] Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. ^[6] Bristol Haematology and Oncology Centre, Bristol, UK. ^[7] Department of Cancer Immunology, Poznan University for Medical Sciences, Med-POLONIA, Poznan, Poland. ^[8] Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland. ^[9] Melanoma Translational Research Group, Melanoma Institute Australia, Wollstonecraft, NSW, Australia. ^[10] Genentech, Inc, South San Francisco, CA, USA. ^[11] Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany. ^[12]